These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 23278214)

  • 1. Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms.
    Polverelli N; Palandri F; Iacobucci I; Catani L; Martinelli G; Vianelli N
    Br J Haematol; 2013 Apr; 161(1):142-4. PubMed ID: 23278214
    [No Abstract]   [Full Text] [Related]  

  • 2. Thrombopoietin-receptor agonists for immune thrombocytopenia.
    Jansen AJ; Swart RM; te Boekhorst PA
    N Engl J Med; 2011 Dec; 365(23):2240-1. PubMed ID: 22150056
    [No Abstract]   [Full Text] [Related]  

  • 3. Thrombopoietin-receptor agonists for primary immune thrombocytopenia.
    Imbach P; Crowther M
    N Engl J Med; 2011 Aug; 365(8):734-41. PubMed ID: 21864167
    [No Abstract]   [Full Text] [Related]  

  • 4. Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus.
    Magnano L; Enríquez H; Esteve J; Cervera R; Espinosa G
    J Rheumatol; 2014 Sep; 41(9):1895-6. PubMed ID: 25179983
    [No Abstract]   [Full Text] [Related]  

  • 5. Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration.
    Arumugaswamy A; He S; Quach H; Brotchie J; Grigg A
    Intern Med J; 2014 May; 44(5):519-21. PubMed ID: 24816314
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical outcomes in eight patients with immune thrombocytopenia each treated with the three approved thrombopoietin receptor agonists.
    Lee EJ; Seshadri M; Bussel JB
    Am J Hematol; 2021 Oct; 96(10):E373-E376. PubMed ID: 34152624
    [No Abstract]   [Full Text] [Related]  

  • 7. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.
    González KJ; Zuluaga SO; DaRos CV; Rodríguez PP; Martí AC
    Ann Hematol; 2017 Mar; 96(3):507-508. PubMed ID: 27975127
    [No Abstract]   [Full Text] [Related]  

  • 8. [Development of thrombopoietin receptor agonists].
    Miyakawa Y
    Rinsho Ketsueki; 2009 Oct; 50(10):1434-43. PubMed ID: 19915352
    [No Abstract]   [Full Text] [Related]  

  • 9. Thrombopoietin receptor activation, thrombopoietin mimetic drugs, and hereditary thrombocytosis: remarks on bone marrow fibrosis.
    Teofili L; Giona F; Martini M; Torti L; Cenci T; Foà R; Leone G; Larocca LM
    J Clin Oncol; 2010 Jul; 28(19):e317-8. PubMed ID: 20516451
    [No Abstract]   [Full Text] [Related]  

  • 10. Current status of thrombopoietic agents.
    Rhodes E; Stasi R
    Expert Rev Hematol; 2010 Apr; 3(2):217-25. PubMed ID: 21083464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired amegakaryocytic thrombocytopenia: potential role of thrombopoietin receptor agonists.
    Lown R; Rhodes E; Bosworth J; Shannon MS; Stasi R
    Clin Adv Hematol Oncol; 2010 Nov; 8(11):809-12. PubMed ID: 21326159
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
    Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H
    Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
    [No Abstract]   [Full Text] [Related]  

  • 13. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists.
    Ghanima W; Lee SY; Barsam S; Miller A; Sandset PM; Bussel JB
    Br J Haematol; 2012 Sep; 158(6):811-4. PubMed ID: 22816787
    [No Abstract]   [Full Text] [Related]  

  • 15. Treating chemotherapy-induced thrombocytopenia: is it time for oncologists to use thrombopoietin agonists?
    Hassan MN; Waller EK
    Oncology (Williston Park); 2015 Apr; 29(4):295-6. PubMed ID: 25952493
    [No Abstract]   [Full Text] [Related]  

  • 16. [Management of refractory ITP with thrombopoietin receptor agonists].
    Tomiyama Y
    Rinsho Ketsueki; 2011 Aug; 52(8):627-32. PubMed ID: 21897068
    [No Abstract]   [Full Text] [Related]  

  • 17. Thrombopoietin receptor agonists as an emergency treatment for severe newly diagnosed immune thrombocytopenia in children.
    Nolla M; Aladjidi N; Leblanc T; Fernandes H; Ducassou S; Fahd M; Barlogis V; Michel M; Blouin P; Jeziorski E; Benadiba J; Pondarre C; Leverger G; Pasquet M
    Blood; 2021 Jan; 137(1):138-141. PubMed ID: 33410895
    [No Abstract]   [Full Text] [Related]  

  • 18. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study.
    Mahévas M; Fain O; Ebbo M; Roudot-Thoraval F; Limal N; Khellaf M; Schleinitz N; Bierling P; Languille L; Godeau B; Michel M
    Br J Haematol; 2014 Jun; 165(6):865-9. PubMed ID: 24725224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Trombopag for chronic immune thrombocytopenia in a patient previously treated with romiplostim].
    Rodríguez Vargas B; Serna Pérez J; Bermejo Vicedo T
    Farm Hosp; 2013; 37(3):265-6. PubMed ID: 23789804
    [No Abstract]   [Full Text] [Related]  

  • 20. Thrombopoietin-receptor agonists.
    Basciano PA; Bussel JB
    Curr Opin Hematol; 2012 Sep; 19(5):392-8. PubMed ID: 22872157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.